ArcticZymes considerably extends patent protection on its heat-labile dsDNase product in several major countries and regions

ArcticZymes AS, a subsidiary of Biotec Pharmacon ASA, has received Notices of Allowance for patent protection of its heat-labile dsDNase product in Europe, China, Japan, South Korea, Australia and Russia.

In addition to the previously published approval of the patent in the USA, the new patents in all these countries and regions will position ArcticZymes strongly on a global basis with this highly innovative product. The patents cover a variety of valuable patent claims including the nucleic acid sequence of the … continue reading »

Woulgan – events and exhibitions

In connection with commercialization of Woulgan, Biotec BetaGlucans will attend the following  conferences and events.

«Framtidens sårbehandling»
Stockholm, Sweden
12th – 13th Oct 2015

Participants: Dag Grønvoll and Alexander Bjørnå.

Wounds UK Annual Conference 2015
Harrogate, UK
9th – 11th Nov 2015

Participants: Dag Grønvoll together with H&R Healthcare, distributor of Woulgan for UK and Ireland

Deutsche WundCongress 2015
Køln, Germany
26th Nov 2015

Participants: Dag Grønvoll and Alexander Bjørnå.

EWMA – European Wound Management Association
Bremen, Germany
11th – 13th May 2016

Enters into UK distribution agreement for Woulgan® with H&R Healthcare

Biotec Pharmacon ASA (”Biotec”, OSE: BIOTEC) has entered into a Woulgan® distribution agreement with leading UK distributor H&R Healthcare Ltd (“H&R Healthcare”, “H&R”). The agreement represents a milestone in the strategy of securing strong regional business partners for Woulgan®.

– Biotec is pleased to announce H&R Healthcare as our partner in the UK and Ireland for the distribution of Woulgan®. H&R is a leading distributor of specialized wound care products and we look forward working closely with them to introduce Woulgan® … continue reading »

Limited offer to buy 10 tubes of Woulgan® for NOK 350

In connection with Biotec Pharmacon’s 2nd quarter 2015 presentation, all shareholders as of 13th August 2015 are invited to buy 10 tubes of Woulgan® for NOK 350,- (inc. taxes, ex shipping) for a limited time.

Biotec hope most shareholders have a chance to use and try this unique product and share it with other interested parties as the Company has strong beliefs in Woulgan®.

If you want to take advantage of this offering, please visit Woulgan’s webshop and type “shareholder1” (all … continue reading »

Presentation of Q2 2015 results

Biotec Pharmacon presents its report for the second quarter 2015 on Thursday, 13 August The presentation will be given by CEO Svein Lien. The presentation starts at 08:30 am and will be in Norwegian.

Venue: Hotell Continental, Stortingsgata 24, Oslo.

The presentation can also be followed as a live webcast from Hegnar TV and it will be possible to post questions through the webcast console at the end of the presentation.

The interim report for the second quarter 2015 will be available on … continue reading »

Update on Woulgan® distribution agreement processes

(Tromsø, 7th July 2015) Biotec Pharmacon ASA (”Biotec”, OSE: BIOTEC) and Smith & Nephew have today mutually decided to end the discussion about a Woulgan® distribution agreement. Consequently, Biotec will therefore accelerate the on-going process to pursue an alternative market channel strategy, which would include distribution agreements with strong regional business partners and distributors.

– Following a period of thorough and constructive discussion with Smith & Nephew, the parties have concluded not to enter into an exclusive commercial agreement for … continue reading »